SunTrust Banks, Inc. set a $9.00 price objective on MediWound Ltd. (NASDAQ:MDWD) in a research report report published on Thursday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also issued reports on the stock. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $10.00 price target on shares of MediWound in a research report on Monday, September 18th. ValuEngine lowered shares of MediWound from a sell rating to a strong sell rating in a research report on Friday, September 22nd. Zacks Investment Research raised shares of MediWound from a strong sell rating to a hold rating in a research report on Wednesday, August 2nd. Cowen and Company initiated coverage on shares of MediWound in a research report on Thursday, September 28th. They set an outperform rating and a $9.00 price target on the stock. Finally, Jefferies Group LLC reaffirmed a buy rating and set a $10.00 price target on shares of MediWound in a research report on Thursday, September 28th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $9.13.
MediWound (MDWD) opened at $4.60 on Thursday. MediWound has a 1-year low of $4.15 and a 1-year high of $8.25.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.